Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.

[1]  Yuan Zhang,et al.  Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection. , 2016, Vaccine.

[2]  K. Kedzierska,et al.  Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization. , 2015, Vaccine.

[3]  Young‐Tae Lee,et al.  Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells , 2015, Journal of Virology.

[4]  M. Moore,et al.  Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract , 2015, PloS one.

[5]  D. Meyerholz,et al.  RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets , 2015, PLoS pathogens.

[6]  R. Compans,et al.  Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. , 2014, Antiviral research.

[7]  Iebe Rossey,et al.  CD8+ T cell immunity against human respiratory syncytial virus. , 2014, Vaccine.

[8]  Jian-Dong Li,et al.  Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. , 2014, Antiviral research.

[9]  K. Poehling,et al.  Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of Age , 2013, Pediatrics.

[10]  S. Baets,et al.  Hepatitis B core–based virus–like particles to present heterologous epitopes , 2013, Expert review of vaccines.

[11]  Milena Dunal-Szczepaniak,et al.  RSV respiratory infection in children under 5 y.o.--dynamics of the immune response Th1/Th2 and IgE. , 2013, Przeglad epidemiologiczny.

[12]  E. Celis,et al.  Vaccine-Elicited CD8+ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice , 2012, Journal of Virology.

[13]  A. Robert,et al.  The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents , 2012, PloS one.

[14]  R. Compans,et al.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. , 2011, The Journal of infectious diseases.

[15]  Y. Nogi,et al.  The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus. , 2011, Antiviral research.

[16]  R. Peebles,et al.  Differential Pathogenesis of Respiratory Syncytial Virus Clinical Isolates in BALB/c Mice , 2011, Journal of Virology.

[17]  B. Graham.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development , 2011, Immunological reviews.

[18]  Marianne Manchester,et al.  Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[19]  E. Kurt-Jones,et al.  Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins , 2010, Journal of Virology.

[20]  J. Rossen,et al.  Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community† , 2010, Journal of medical virology.

[21]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[22]  L. Shen,et al.  A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK. , 2009, Vaccine.

[23]  I. M. Belyakov,et al.  What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens? , 2009, The Journal of Immunology.

[24]  A. Fraire,et al.  Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology , 2009, Journal of Virology.

[25]  L. Anderson,et al.  Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice , 2009, Journal of Virology.

[26]  P. Chong,et al.  Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. , 2009, Vaccine.

[27]  B. Graham,et al.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. , 2009, Vaccine.

[28]  P. Tien,et al.  Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. , 2009, Antiviral research.

[29]  J. Kohlmeier,et al.  Migration, maintenance and recall of memory T cells in peripheral tissues , 2009, Nature Reviews Immunology.

[30]  S. Varga,et al.  The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia1 , 2008, The Journal of Immunology.

[31]  R. Walker,et al.  Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. , 2008, Vaccine.

[32]  B. Graham,et al.  Pulmonary eosinophilia requires interleukin‐5, eotaxin‐1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein , 2008, Journal of leukocyte biology.

[33]  M. Nassal,et al.  Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. , 2008, International journal of medical microbiology : IJMM.

[34]  K. Boyd,et al.  Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. , 2007, Vaccine.

[35]  K. Uberla,et al.  Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. , 2007, Vaccine.

[36]  R. Johnston,et al.  Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats , 2007, Journal of Virology.

[37]  S. Sahi,et al.  Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. , 2007, Vaccine.

[38]  T. Mukherjee,et al.  Role of TNFα in pulmonary pathophysiology , 2006, Respiratory Research.

[39]  B. Böttcher,et al.  Hepatitis B Virus Capsid-like Particles Can Display the Complete, Dimeric Outer Surface Protein C and Stimulate Production of Protective Antibody Responses against Borrelia burgdorferi Infection* , 2006, Journal of Biological Chemistry.

[40]  G. Prince,et al.  The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. , 2006, Vaccine.

[41]  J. Tregoning,et al.  Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection , 2005, Clinical Microbiology Reviews.

[42]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[43]  M. Nassal,et al.  A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula , 2005, European journal of immunology.

[44]  B. Graham,et al.  Pathogenesis of respiratory syncytial virus infection in the murine model. , 2005, Proceedings of the American Thoracic Society.

[45]  B. Graham,et al.  Prolonged Production of TNF-α Exacerbates Illness during Respiratory Syncytial Virus Infection1 , 2004, The Journal of Immunology.

[46]  K. Boyd,et al.  Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSV , 2004, Journal of Virology.

[47]  Derick R. Peterson,et al.  Risk factors for severe respiratory syncytial virus infection in elderly persons. , 2004, The Journal of infectious diseases.

[48]  P. Piedra,et al.  Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. , 2003, Vaccine.

[49]  S. Davis,et al.  Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. , 2003, Vaccine.

[50]  R. Parker,et al.  IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge 1 , 2003, The Journal of Immunology.

[51]  T. Braciale,et al.  Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. , 2001, Immunity.

[52]  T. Nguyen,et al.  Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein. , 2001, Vaccine.

[53]  Gerhard Walzl,et al.  Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses1 , 2001, The Journal of Immunology.

[54]  T. Braciale,et al.  The Attachment (G) Glycoprotein of Respiratory Syncytial Virus Contains a Single Immunodominant Epitope That Elicits Both Th1 and Th2 CD4+ T Cell Responses1 , 2000, The Journal of Immunology.

[55]  P. Stang,et al.  Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. , 2000, The Journal of pediatrics.

[56]  M. Parrington,et al.  Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. , 2000, Virology.

[57]  T. Braciale,et al.  Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent , 1999, Journal of Virology.

[58]  B. Böttcher,et al.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Hagen,et al.  Atypical Pulmonary Eosinophilia Is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus , 1998, The Journal of experimental medicine.

[60]  B. García-Barreno,et al.  Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia , 1998, The Journal of experimental medicine.

[61]  J. Reimann,et al.  Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses. , 1998, Vaccine.

[62]  B. Graham,et al.  Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge , 1998, Journal of Virology.

[63]  D. Chargelegue,et al.  Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. , 1998, Virology.

[64]  T. Braciale,et al.  Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection , 1997, The Journal of experimental medicine.

[65]  T. Braciale,et al.  Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection , 1997, Journal of virology.

[66]  J. Smith,et al.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus , 1996, Journal of virology.

[67]  B. Murphy,et al.  Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus , 1995, Journal of virology.

[68]  R. Chanock,et al.  Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. , 1995, Vaccine.

[69]  J. Dopazo,et al.  Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein , 1994, Journal of virology.

[70]  B. Murphy,et al.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10 , 1994, Journal of virology.

[71]  R. A. Crowther,et al.  Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy , 1994, Cell.

[72]  B. Murphy,et al.  The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice , 1993, Journal of virology.

[73]  B. Murphy,et al.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells , 1992, Journal of virology.

[74]  L. Anderson,et al.  Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses , 1991, Journal of virology.

[75]  D. Matthews,et al.  Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. , 1991, The Journal of general virology.

[76]  E. Walsh,et al.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity , 1988, Journal of clinical microbiology.

[77]  E. Walsh,et al.  Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine , 1986, Journal of clinical microbiology.

[78]  R. Chanock,et al.  Cell-mediated Immunity to Respiratory Syncytial Virus Induced by Inactivated Vaccine or by Infection , 1976, Pediatric Research.

[79]  R. Chanock,et al.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. , 1969, American journal of epidemiology.

[80]  E. H. Lennette,et al.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.